Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Rudd announces funds for north coast NSW cancer centers

Prime Minister Kevin Rudd had announced a regional cancer center in the mid-north coast on Tuesday at Port Macquarie. He says plans are underway to invest almost $5 million for a second linear accelerator at the Port Base Hospital.

16 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

13 Apr 2010

EDAP's Sonolith i-move lithotripter receives European approval

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the European approval of its new lithotripter, the Sonolith i-move. The EDAP sales team and distributors will begin marketing Sonolith i-move immediately and will officially introduce the product to distributors, partners and visiting urologists at the European Association Urology (EAU) congress, Booth #14, from April 17-19, 2010 in Barcelona, Spain.

12 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

12 Apr 2010

Patients with end-stage cancer do not benefit from palliative radiotherapy: CANCER

A new analysis has found that a considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation therapy despite spending most of their remaining life undergoing treatments. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer.

12 Apr 2010

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya's IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).

8 Apr 2010

Blocking POLQ gene activity can increase ability of radiotherapy to destroy tumours

Cancer Research UK scientists have identified a gene that once blocked could increase the effectiveness of radiotherapy on tumours, according to research published in Cancer Research today (Thursday).

7 Apr 2010

20 regional cancer care units to get $560 million for upgrades

There is good news for millions of cancer patients across Australia. Prime Minister Rudd has announced a contribution of $560 million with the intention of upgrading and opening new cancer centers in regional and rural communities all over Australia.

7 Apr 2010

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

BioAlliance Pharma SA signs partnership agreement with Therabel Group

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.

6 Apr 2010

SBRT effective in primary tumor control, study finds

Many of the world's leading radiation oncologists are employing the unique capabilities of SBRT to treat a variety of cancers that often have defied conventional radiation therapy techniques. A multitude of studies evaluating SBRT are ongoing and investigators are publishing articles that demonstrate the effectiveness of this technique. Two studies led by renowned radiation oncologists were conducted at centers that use Elekta SBRT technology, and their results were published recently.

From Elekta 2 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

EvoLife Laboratories introduces cancer care products in USA

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, announced the launch of its products in USA.

31 Mar 2010

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Former England Rugby World Cup winner Matt Dawson today launched the 'Because Life is for Living' campaign to raise awareness about brachytherapy, a very precise and highly effective form of radiotherapy to treat cancer.

30 Mar 2010

Kylie Minogue supports breast cancer initiative

Australian singer Kylie Minogue is part of this year’s Fashion Targets Breast Cancer campaign. Kylie is a cancer survivor who was diagnosed with the disease in May 2005. She had to cancel her Showgirl world tour’s Australian leg because of that.

30 Mar 2010

Six weeks of radiotherapy to be consolidated into 30 minutes for breast cancer patients

Nearly 45 thousand women are diagnosed with breast cancer each year. Two third of these women need a combination of surgery and radiotherapy. Radiotherapy can kill cancer cells that may have been missed during operation. These remnant cells are responsible for 90% relapses.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Radiotherapy News and Research

Further Reading

Rudd announces funds for north coast NSW cancer centers

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Despite international guidelines, wide variations exist in breast cancer care

EDAP's Sonolith i-move lithotripter receives European approval

Global study shows wide variations in treatment of women with early breast cancer

Patients with end-stage cancer do not benefit from palliative radiotherapy: CANCER

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Blocking POLQ gene activity can increase ability of radiotherapy to destroy tumours

20 regional cancer care units to get $560 million for upgrades

Src can be most promising targets for cancer therapy

BioAlliance Pharma SA signs partnership agreement with Therabel Group

SBRT effective in primary tumor control, study finds

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

EvoLife Laboratories introduces cancer care products in USA

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Kylie Minogue supports breast cancer initiative

Six weeks of radiotherapy to be consolidated into 30 minutes for breast cancer patients

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Cancer Research eBook

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News